Structure of the Epstein-Barr virus major envelope glycoprotein

Epstein-Barr virus (EBV) infection of B cells is associated with lymphoma and other human cancers. EBV infection is initiated by the binding of the viral envelope glycoprotein (gp350) to the cell surface receptor CR2. We determined the X-ray structure of the highly glycosylated gp350 and defined the CR2 binding site on gp350. Polyglycans shield all but one surface of the gp350 polypeptide, and we demonstrate that this glycan-free surface is the receptor-binding site. Deglycosylated gp350 bound CR2 similarly to the glycosylated form, suggesting that glycosylation is not important for receptor binding. Structure-guided mutagenesis of the glycan-free surface disrupted receptor binding as well as binding by a gp350 monoclonal antibody, a known inhibitor of virus-receptor interactions. These results provide structural information for developing drugs and vaccines to prevent infection by EBV and related viruses.

[1]  J. Tarlton,et al.  Distribution of epitopes within the amino acid sequence of the Epstein-Barr virus major envelope glycoprotein, gp340, recognized by hyperimmune rabbit sera. , 1992, The Journal of general virology.

[2]  Rengasamy Asokan,et al.  Mutational analysis of the complement receptor type 2 (CR2/CD21)-C3d interaction reveals a putative charged SCR1 binding site for C3d. , 2005, Journal of molecular biology.

[3]  G. Nemerow,et al.  Identification of an epitope in the major envelope protein of Epstein-Barr virus that mediates viral binding to the B lymphocyte EBV receptor (CR2) , 1989, Cell.

[4]  B. Griffin.  Epstein-Barr virus (EBV) and human disease: facts, opinions and problems. , 2000, Mutation research.

[5]  G. Bricogne,et al.  [27] Maximum-likelihood heavy-atom parameter refinement for multiple isomorphous replacement and multiwavelength anomalous diffraction methods. , 1997, Methods in enzymology.

[6]  G. Nemerow,et al.  Soluble recombinant CR2 (CD21) inhibits Epstein-Barr virus infection , 1990, Journal of Virology.

[7]  T. Stehle,et al.  The crystal structure of human CD21: Implications for Epstein–Barr virus and C3d binding , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[8]  K. Constantine,et al.  Solution structure of human CTLA-4 and delineation of a CD80/CD86 binding site conserved in CD28 , 1997, Nature Structural Biology.

[9]  W. T. Moore,et al.  Kinetic Analysis of the Interactions of Complement Receptor 2 (CR2, CD21) with Its Ligands C3d, iC3b, and the EBV Glycoprotein gp350/2201 , 2001, The Journal of Immunology.

[10]  Thomas C. Terwilliger,et al.  Automated MAD and MIR structure solution , 1999, Acta crystallographica. Section D, Biological crystallography.

[11]  D. Fearon,et al.  Suppression of the immune response by a soluble complement receptor of B lymphocytes. , 1991, Science.

[12]  D. Fearon,et al.  Mapping of the Epstein-Barr virus and C3dg binding sites to a common domain on complement receptor type 2 , 1989, The Journal of experimental medicine.

[13]  D. Fearon,et al.  Identification of a 145,000 Mr membrane protein as the C3d receptor (CR2) of human B lymphocytes. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[14]  G. Ippolito,et al.  Infection with Epstein-Barr virus and cancer: an epidemiological review. , 2005, Journal of biological regulators and homeostatic agents.

[15]  T. Jardetzky,et al.  Structure of the Epstein-Barr virus gp42 protein bound to the MHC class II receptor HLA-DR1. , 2002, Molecular cell.

[16]  M. Patarroyo,et al.  Identification of Three gp350/220 Regions Involved in Epstein-Barr Virus Invasion of Host Cells* , 2005, Journal of Biological Chemistry.

[17]  D. Thorley-Lawson,et al.  Monoclonal antibodies against the major glycoprotein (gp350/220) of Epstein-Barr virus neutralize infectivity. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[18]  E. Kieff,et al.  Soluble gp350/220 and deletion mutant glycoproteins block Epstein-Barr virus adsorption to lymphocytes , 1988, Journal of virology.

[19]  P. A. Biro,et al.  Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[20]  L. Young,et al.  Epstein–Barr virus: 40 years on , 2004, Nature Reviews Cancer.

[21]  L. Hutt-Fletcher,et al.  Epstein-Barr Virus gH Is Essential for Penetration of B Cells but Also Plays a Role in Attachment of Virus to Epithelial Cells , 2000, Journal of Virology.

[22]  E. Kieff,et al.  Epstein-barr virus gp350/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping, and endocytosis , 1987, Cell.

[23]  J. Tarlton,et al.  Protective immunization against Epstein-Barr virus-induced disease in cottontop tamarins using the virus envelope glycoprotein gp340 produced from a bovine papillomavirus expression vector. , 1992, The Journal of general virology.

[24]  T. Okuno.  An epidemiological review of Japanese encephalitis. , 1978, World health statistics quarterly. Rapport trimestriel de statistiques sanitaires mondiales.

[25]  B. Nagar,et al.  X-ray crystal structure of C3d: a C3 fragment and ligand for complement receptor 2. , 1998, Science.

[26]  R. Spaete,et al.  Expression of Epstein-Barr virus gp350 as a single chain glycoprotein for an EBV subunit vaccine. , 1999, Vaccine.

[27]  R. Miller,et al.  Progressive intrathoracic lymphadenopathy: EBV associated non-Hodgkin's lymphoma , 2002, Sexually transmitted infections.

[28]  R J Read,et al.  Crystallography & NMR system: A new software suite for macromolecular structure determination. , 1998, Acta crystallographica. Section D, Biological crystallography.

[29]  W. Schleif,et al.  Vero cell‐expressed Epstein‐Barr virus (EBV) gp350/220 protects marmosets from EBV challenge , 1989, Journal of medical virology.

[30]  C. Marcus-Sekura,et al.  Conformation-dependent recognition of baculovirus-expressed Epstein-Barr virus gp350 by a panel of monoclonal antibodies. , 1993, The Journal of general virology.

[31]  V. Michael Holers,et al.  Structure of Complement Receptor 2 in Complex with Its C3d Ligand , 2001, Science.

[32]  Martin A. Nowak,et al.  Antibody neutralization and escape by HIV-1 , 2003, Nature.

[33]  John D Lambris,et al.  Epitope Mapping Using the X-Ray Crystallographic Structure of Complement Receptor Type 2 (CR2)/CD21: Identification of a Highly Inhibitory Monoclonal Antibody That Directly Recognizes the CR2-C3d Interface1 , 2001, The Journal of Immunology.

[34]  D. Fearon,et al.  Epstein-Barr virus (EBV) infection of murine L cells expressing recombinant human EBV/C3d receptor. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[35]  M. Betenbaugh,et al.  Differential N-Glycan Patterns of Secreted and Intracellular IgG Produced in Trichoplusia ni Cells* , 1997, The Journal of Biological Chemistry.